Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (191-200 of 467) with videos related to

Pageof 47
Sort By:
The New Microbiologica|January 5, 2007
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patientsHamid Hasson, Priscilla Biswas, Laura Galli, et al.
AIDS (London, England)|August 10, 2012
Polyclonal serum-free light chains elevation in HIV-infected patientsMichele Bibas, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The New Microbiologica|May 3, 2024
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests"Francesca Panza, Francesco Saladini, Niccolò Bartolini, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2019
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)Antonella Castagna, Camilla Muccini, Laura Galli, et al.
The New Microbiologica|January 3, 2006
In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patientsNicola Gianotti, Laura Galli, Enzo Boeri, et al.
AIDS (London, England)|January 25, 2013
B-cell subset alterations and correlated factors in HIV-1 infectionSimone Pensieroso, Laura Galli, Silvia Nozza, et al.
Journal of the International AIDS Society|November 15, 2014
Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppressionAlessia Carbone, Laura Galli, Alba Bigoloni, et al.
Clinical Nutrition (Edinburgh, Scotland)|July 30, 2013
Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular riskLaura Galli, Alessandro Rubinacci, Deborah Cocorullo, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2025
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, ItalyAngelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, et al.
Open Forum Infectious Diseases|January 12, 2019
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIVVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
Pageof 47

Showing results (191-200 of 467) with videos related to

Sort By:
Pageof 47
The New Microbiologica|January 5, 2007
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patientsHamid Hasson, Priscilla Biswas, Laura Galli, et al.
AIDS (London, England)|August 10, 2012
Polyclonal serum-free light chains elevation in HIV-infected patientsMichele Bibas, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The New Microbiologica|May 3, 2024
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests"Francesca Panza, Francesco Saladini, Niccolò Bartolini, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2019
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)Antonella Castagna, Camilla Muccini, Laura Galli, et al.
The New Microbiologica|January 3, 2006
In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patientsNicola Gianotti, Laura Galli, Enzo Boeri, et al.
AIDS (London, England)|January 25, 2013
B-cell subset alterations and correlated factors in HIV-1 infectionSimone Pensieroso, Laura Galli, Silvia Nozza, et al.
Journal of the International AIDS Society|November 15, 2014
Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppressionAlessia Carbone, Laura Galli, Alba Bigoloni, et al.
Clinical Nutrition (Edinburgh, Scotland)|July 30, 2013
Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular riskLaura Galli, Alessandro Rubinacci, Deborah Cocorullo, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2025
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, ItalyAngelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, et al.
Open Forum Infectious Diseases|January 12, 2019
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIVVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
Pageof 47